Organon & Co. (historical, later spun off)

E468962

Organon & Co. (historical, later spun off) was Merck & Co.’s women’s health and biosimilars-focused business unit that was separated into an independent pharmaceutical company.

All labels observed (2)

How this entity was disambiguated

Statements (30)

Predicate Object
instanceOf business unit
pharmaceutical business unit
businessType biosimilars-focused business unit
women’s health-focused business unit
corporateAction separation of women’s health and biosimilars portfolio from Merck & Co.
corporateRelationship was internal business segment prior to spin-off
countryOfParentCompany United States NERFINISHED
focusArea biosimilars
women’s health
industry pharmaceuticals
parentCompany Merck & Co., Inc. NERFINISHED
parentCompanyAlsoKnownAs Merck Sharp & Dohme (MSD) outside the United States and Canada NERFINISHED
parentCompanyTicker MRK NERFINISHED
partOf Merck & Co., Inc. NERFINISHED
predecessorOf Organon & Co. (independent company) NERFINISHED
productType biosimilar medicines
pharmaceutical products
reasonForSpinOff to create a standalone company focused on women’s health and biosimilars
roleWithinParent specialized operating unit
separationType corporate spin-off
spunOffInto Organon & Co. (independent company) NERFINISHED
statusAfterSpinOff no longer a business unit of Merck & Co.; operations transferred to independent Organon & Co.
successorCompanyFocus biosimilars
women’s health
successorCompanyIndustry global pharmaceutical company
successorCompanyName Organon & Co. NERFINISHED
therapeuticArea contraception
fertility
menopause management
reproductive health

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

Merck & Co. hasSubsidiary Organon & Co. (historical, later spun off)
Merck & Co. spunOff Organon & Co. (historical, later spun off)
this entity surface form: Organon & Co.